Condition: Small-cell Lung Cancer · Small Cell Lung Carcinoma · Sponsor: University of Maryland, Baltimore
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
This description comes directly from the study's public registry record.
Amelia Barkman, MHA · 410-328-5009 · amelia.barkman@umm.edu
Maha Khalil · 410-328-5009 · Mkhalil@umm.edu
Always discuss trial participation with your own doctor first.
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05450965